148 related articles for article (PubMed ID: 16127623)
1. American Society of Clinical Oncology--35th annual meeting. 15-18 May 1999, Atlanta, GA, USA.
Boven E
IDrugs; 1999 Jul; 2(7):617-9. PubMed ID: 16127623
[TBL] [Abstract][Full Text] [Related]
2. Gene therapy and immunotherapy.
McKinnon C
IDrugs; 1999 Jul; 2(7):620-3. PubMed ID: 16127624
[TBL] [Abstract][Full Text] [Related]
3. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
Berry J
Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
[TBL] [Abstract][Full Text] [Related]
4. Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
Gralow J; Ozols RF; Bajorin DF; Cheson BD; Sandler HM; Winer EP; Bonner J; Demetri GD; Curran W; Ganz PA; Kramer BS; Kris MG; Markman M; Mayer RJ; Raghavan D; Ramsey S; Reaman GH; Sawaya R; Schuchter LM; Sweetenham JW; Vahdat LT; Davidson NE; Schilsky RL; Lichter AS;
J Clin Oncol; 2008 Jan; 26(2):313-25. PubMed ID: 18086794
[TBL] [Abstract][Full Text] [Related]
5. American Association for Cancer Research--90th annual meeting. 10-14 April 1999, Philadelphia, PA, USA.
Boven E
IDrugs; 1999 Jun; 2(6):530-3. PubMed ID: 16127610
[TBL] [Abstract][Full Text] [Related]
6. A randomized phase III comparative trial of immediate consolidation with high-dose chemotherapy and autologous peripheral blood progenitor cell support compared to observation with delayed consolidation in women with metastatic breast cancer and only bone metastases following intensive induction chemotherapy.
Vredenburgh JJ; Madan B; Coniglio D; Ross M; Broadwater G; Niedzwiecki D; Edwards J; Marks L; Vandemark R; McDonald C; Affronti ML; Peters WP
Bone Marrow Transplant; 2006 Jun; 37(11):1009-15. PubMed ID: 16633363
[TBL] [Abstract][Full Text] [Related]
7. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
; Tanner M; Isola J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmström P; Wilking N; Nilsson J; Bergh J
J Clin Oncol; 2006 Jun; 24(16):2428-36. PubMed ID: 16682728
[TBL] [Abstract][Full Text] [Related]
8. Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women.
Pentheroudakis G; Fountzilas G; Bafaloukos D; Koutsoukou V; Pectasides D; Skarlos D; Samantas E; Kalofonos HP; Gogas H; Pavlidis N
Breast Cancer Res Treat; 2006 Jun; 97(3):237-44. PubMed ID: 16322882
[TBL] [Abstract][Full Text] [Related]
9. New agents for colon and breast cancer.
McKinnon C
IDrugs; 1998 Jun; 1(2):168-71. PubMed ID: 18465523
[TBL] [Abstract][Full Text] [Related]
10. American Society of Gene Therapy--First Annual Meeting. Education session: the ABCs of non-viral vectors for gene therapy. 28-31 May 1998, Seattle, Washington, USA.
Hutchinson E
IDrugs; 1998 Jul; 1(3):265-7. PubMed ID: 18465541
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant androgen deprivation therapy augments cure and long-term cancer control in men with poor prognosis, nonmetastatic prostate cancer.
Fleshner N; Keane TE; Lawton CA; Mulders PF; Payne H; Taneja SS; Morris T
Prostate Cancer Prostatic Dis; 2008; 11(1):46-52. PubMed ID: 17607304
[TBL] [Abstract][Full Text] [Related]
12. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
13. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
Medina PJ; Goodin S
Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
[TBL] [Abstract][Full Text] [Related]
14. American Society of Clinical Oncology--34th Annual Meeting. Treatments for prostate cancer and new molecular targets. 16-19 May 1998, Los Angeles, California, USA.
McKinnon C
IDrugs; 1998 Jun; 1(2):163-7. PubMed ID: 18465522
[TBL] [Abstract][Full Text] [Related]
15. Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 years.
Hanrahan EO; Broglio K; Frye D; Buzdar AU; Theriault RL; Valero V; Booser DJ; Singletary SE; Strom EA; Gajewski JL; Champlin RE; Hortobagyi GN
Cancer; 2006 Jun; 106(11):2327-36. PubMed ID: 16639731
[TBL] [Abstract][Full Text] [Related]
16. Extended adjuvant endocrine therapy of early breast cancer.
Chowdhury S; Ellis P
Curr Med Res Opin; 2005 Dec; 21(12):1985-95. PubMed ID: 16368050
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant therapy for breast cancer.
Hennessy BT; Pusztai L
Minerva Ginecol; 2005 Jun; 57(3):305-26. PubMed ID: 16166938
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant therapy of melanoma.
Shah GD; Chapman PB
Cancer J; 2007; 13(3):217-22. PubMed ID: 17620773
[TBL] [Abstract][Full Text] [Related]
19. Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16.
Crump M; Gluck S; Tu D; Stewart D; Levine M; Kirkbride P; Dancey J; O'Reilly S; Shore T; Couban S; Girouard C; Marlin S; Shepherd L; Pritchard KI
J Clin Oncol; 2008 Jan; 26(1):37-43. PubMed ID: 18025439
[TBL] [Abstract][Full Text] [Related]
20. [The 4th large meta-analysis of all trials of the treatment of operable breast cancer: increased survival after a longer follow-up].
van Nes JG; Nortier WR; van de Velde CJ
Ned Tijdschr Geneeskd; 2005 Sep; 149(36):1978-80. PubMed ID: 16171107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
